PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

This multicenter retrospective study developed and validated a prediction model based on PSMA PET/CT and routine clinical information to estimate early treatment response in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving first-line standard therapy. Existing PSMA PET/CT scans were used to quantify tumor burden, and imaging metrics were combined with baseline clinical factors, including laboratory results and disease characteristics, to build an interpretable model for predicting the likelihood and timing of achieving a deep PSA response (PSA ≤ 0.2 ng/mL) after initiation of first-line treatment. All data were collected from medical records and imaging obtained as part of routine care; no additional tests or treatments were required. The objective was to improve risk stratification and support individualized follow-up and treatment planning for patients with mHSPC.

NCT Number	NCT07428642
Lead Sponsor	First Affiliated Hospital of Wenzhou Medical University Collaborators: Second Affiliated Hospital of Wenzhou Medical University, Ningbo No. 1 Hospital, Lishui Country People's Hospital, Sun Yat-Sen University Cancer Center
Conditions	Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer
Enrollment	168 participants
Start Date	2020-09-01
Primary Completion	2025-12-03 (estimated)
Study Completion	2025-12-03 (estimated)
Updated on ClinicalTrials.gov	2026-03-18